Half Yearly Report and Accounts
Half Yearly Report and Accounts
Brisbane, Feb 22, 2018 AEST (ABN Newswire) - Anatara Lifesciences (ASX:ANR) today released its Appendix 4D financial report for the half year ending 31st December 2017.

Highlights from the period include:

- Global animal health company, Zoetis Inc, exercising its option to negotiate a commercial agreement for the worldwide development, distribution and marketing of Detach(R).

- Establishing an experienced veterinary team focused on launching Detach(R) into the anti-diarrhoeal therapeutic pig market.

- Developing a proprietary dosing device for the optimal delivery of Detach(R) by pig farmers

- Presenting at the Australasian Pig Science Association (APSA) Conference - highlighting the comparable efficacy of Detach(R) to in-feed Zinc Oxide

- Increasing focus on human opportunities through the development of proprietary products for the management of diarrhoea associated with gastrointestinal disorders

To view the full report, please visit:

About Anatara Lifesciences Ltd

Anatara Lifesciences ASX ANRAnatara Lifesciences (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. For more information, please visit www.anataralifesciences.com.



Investor inquiries:
Dr Mel Bridges
Chairman & CEO, Anatara Lifesciences
Phone: +61-413-051-600
Email: mbridges@anatara.com

Media inquiries:
Jane Lowe
Managing Director, IR Department
Phone: +61-411-117-774
Email: jane.lowe@irdepartment.com.au

Related Companies

Anatara Lifesciences Ltd

ABN Newswire This Page Viewed:  (Last 7 Days: 11) (Last 30 Days: 26) (Since Published: 5167)